J&J Risperdal Consta “non-approvable”
J&J will discuss FDA concerns about pre-clinical data for injectable long-acting antipsychotic Risperdal Consta (risperidone) following receipt of "non-approvable" letter. J&J filed the NDA Aug. 31, 2001...
You may also be interested in...
Johnson & Johnson is finalizing its response to a Risperdal Consta "not approvable" letter received from FDA last year
Alkermes' August rebound on Wall Street suggests that the less-is-more approach is playing well with investors
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.